CD44 and ovarian carcinoma: As MDR1 is the major mechanism for paclitaxel resistance, the combination of MDR1 siRNA CD44 targeted nanoparticle and paclitaxel hold great potential to increase paclitaxel sensitivity/efficacy and overcome MDR in ovarian cancer treatment.